Overview

Safety and Tolerability of GTX-104 Compared With Oral Nimodipine in Patients With aSAH

Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to deliver nimodipine via IV directly into the bloodstream and to determine if this is as safe and tolerable as oral nimodipine capsules.
Phase:
Phase 3
Details
Lead Sponsor:
Acasti Pharma Inc.
Treatments:
Nimodipine